

**Biostatistics\_statement**

**Title:** Teneiglipitin mitigates diabetic cardiomyopathy by inhibiting activation of the NOD-like receptor protein 3 (NLRP3) inflammasome

**MS number:** 88728


This letter is to confirm that I have read the ethics application prepared for this study, and that in my opinion the statistical methods and techniques mentioned are appropriate for the research.

Please contact me if you have any queries.

Sincerely,

**Name:** Lintao Zhong, Zhuhai People's Hospital(Zhuhai hospital affiliated with Jinan University)

**Signature:**



**Contact information: Email:**